{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:03:22Z","timestamp":1773270202355,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC\/ISOO) has published evidence-based international guidelines for the management of oral mucositis (OM). However, adherence to these guidelines has not been evaluated. This survey assessed OM management in hematopoietic cell transplantation (HCT) centers in Australia and New Zealand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Specialist nurses in 41 transplant hospitals were invited to complete a survey. Questions covered general unit information, oral assessment (tools, assessors, frequency), prevention strategies (guidelines, oral care, cryotherapy, photobiomodulation, palifermin, and barriers to use), and treatment strategies (pain management and nutritional support).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 41 hospitals, 24 (59%) responded. All but one responder were specialized nurses. Oral assessment was primarily conducted by nurses (100%) and doctors (80%). The most commonly used tools were the World Health Organization grading scale (42%), pain scores (46%), and EviQ (Australian online cancer resource) (42%). EviQ guidelines (67%), which exclude palifermin and photobiomodulation, followed by institutional guidelines (29%) and MASCC\/ISOO guidelines (17%). Oral care (100%) and cryotherapy with melphalan (96%) were widely adopted, while photobiomodulation and palifermin were rarely used due to cost and access barriers. For OM-related pain, as-needed opioids (100%), patient-controlled analgesia (58%), and topical analgesics (46%) were common. When OM impaired oral intake, supportive measures included supplemental drinks (88%), enteral nutrition (50%), and parenteral nutrition (67%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Australia and New Zealand, national EviQ guidelines are used more often than the MASCC\/ISOO guidelines. Feasibility for implementing palifermin and photobiomodulation should be reassessed, and greater collaboration in developing guidelines is necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10423-5","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:36:14Z","timestamp":1772573774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral mucositis management in hematopoietic cell transplantation in Australia and New Zealand (CAN EAT Survey)"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3936-6637","authenticated-orcid":false,"given":"Emma","family":"Munro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-9852","authenticated-orcid":false,"given":"Nicole C","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-6960","authenticated-orcid":false,"given":"Midori","family":"Nakagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"17","key":"10423_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813\u20131826.\u00a0https:\/\/doi.org\/10.1056\/NEJMra052638","journal-title":"N Engl J Med"},{"key":"10423_CR2","doi-asserted-by":"crossref","unstructured":"Shimoni A, Radici V, Nagler A (2024) Conditioning. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E (eds). The EBMT handbook: hematopoietic cell transplantation and cellular therapies. Springer Cham, pp 125\u201334","DOI":"10.1007\/978-3-031-44080-9_13"},{"issue":"1","key":"10423_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s005209900095","volume":"8","author":"LA Bellm","year":"2000","unstructured":"Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8(1):33\u201339.\u00a0https:\/\/doi.org\/10.1007\/s005209900095","journal-title":"Support Care Cancer"},{"issue":"6","key":"10423_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000487085","volume":"41","author":"K Berger","year":"2018","unstructured":"Berger K, Schopohl D, Bollig A, Strobach D, Rieger C, Rublee D et al (2018) Burden of oral mucositis: a systematic review and implications for future research. Oncol Res Treat 41(6):399\u2013405.\u00a0https:\/\/doi.org\/10.1159\/000487085","journal-title":"Oncol Res Treat"},{"issue":"1","key":"10423_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0609.2011.01724.x","volume":"88","author":"L Facchini","year":"2012","unstructured":"Facchini L, Martino R, Ferrari A, Pinana JL, Valcarcel D, Barba P et al (2012) Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. Eur J Haematol 88(1):46\u201351.\u00a0https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01724.x","journal-title":"Eur J Haematol"},{"issue":"19","key":"10423_CR6","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM et al (2020) MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126(19):4423\u20134431.\u00a0https:\/\/doi.org\/10.1002\/cncr.33100","journal-title":"Cancer"},{"key":"10423_CR7","unstructured":"UK Oral Management in Cancer Care Group (UKOMiC). Oral management guidance (2019) http:\/\/www.ukomic.com. Accessed 7 Feb 2026"},{"key":"10423_CR8","unstructured":"eviQ. Oral mucositis and stomatitis (2025). Available from: https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/oropharyngeal\/210-oral-mucositis-and-stomatitis#assessment.\u00a0Accessed 7 Feb 2026"},{"key":"10423_CR9","doi-asserted-by":"publisher","first-page":"102675","DOI":"10.1016\/j.eclinm.2024.102675","volume":"73","author":"R Abdalla-Aslan","year":"2024","unstructured":"Abdalla-Aslan R, Bonomo P, Keefe D, Blijlevens N, Cao K, Cheung YT et al (2024) Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine 73:102675. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102675","journal-title":"eClinicalMedicine"},{"key":"10423_CR10","unstructured":"World Health Organization (1979) WHO handbook for reporting results of cancer treatment. World Health Organization\u00a0(WHO Offset Publication No. 48)"},{"key":"10423_CR11","unstructured":"National Cancer Institute (NCI) (2025) Common Terminology Criteria for Adverse Event (CTCAE) v6. Available from:\u00a0 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 17 Feb 2025"},{"key":"10423_CR12","unstructured":"Eilers J, Berger AM, Petersen M (eds) (1988) Development, testing, and application of the oral assessment guide. Oncology nursing forum\u00a015(3):325"},{"issue":"9","key":"10423_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/cncr.22620","volume":"109","author":"JB Epstein","year":"2007","unstructured":"Epstein JB, Beaumont JL, Gwede CK, Murphy B, Garden AS, Meredith R et al (2007) Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109(9):1914\u20131922.\u00a0https:\/\/doi.org\/10.1002\/cncr.22620","journal-title":"Cancer"},{"issue":"4","key":"10423_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.bmt.1705250","volume":"37","author":"PJ Stiff","year":"2006","unstructured":"Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J et al (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37(4):393\u2013401.\u00a0https:\/\/doi.org\/10.1038\/sj.bmt.1705250","journal-title":"Bone Marrow Transplant"},{"key":"10423_CR15","unstructured":"National Cancer Institute (NCI) (2024) Patient Reported Outcome Common Terminology Criteria for Adverse Event (PRO-CTCAE). Available from: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/.Accessed 17 Feb 2025"},{"issue":"1","key":"10423_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08235-y","volume":"32","author":"M Nakagaki","year":"2024","unstructured":"Nakagaki M, Kennedy GA, Gavin NC, Butler J, Clavarino A, Whitfield K (2024) A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study). Support Care Cancer 32(1):44.\u00a0https:\/\/doi.org\/10.1007\/s00520-023-08235-y","journal-title":"Support Care Cancer"},{"issue":"25","key":"10423_CR17","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590\u20132598.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa040125","journal-title":"N Engl J Med"},{"issue":"9","key":"10423_CR18","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1182\/blood-2006-04-017780","volume":"108","author":"BR Blazar","year":"2006","unstructured":"Blazar BR, Weisdorf DJ, DeFor T, Goldman A, Braun T, Silver S et al (2006) Phase 1\/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108(9):3216\u20133222.\u00a0https:\/\/doi.org\/10.1182\/blood-2006-04-017780","journal-title":"Blood"},{"issue":"7","key":"10423_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/bmt.2012.257","volume":"48","author":"N Blijlevens","year":"2013","unstructured":"Blijlevens N, De Ch\u00e2teau M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al (2013) In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient\u2019s burden. Bone Marrow Transplant 48(7):966\u2013971.\u00a0https:\/\/doi.org\/10.1038\/bmt.2012.257","journal-title":"Bone Marrow Transplant"},{"key":"10423_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000333305","volume":"34","author":"G Fink","year":"2011","unstructured":"Fink G, Ihorst G, Burbeck M, Kleber M, Kohlweyer U, Engelhardt M (2011) Prospective randomized trial of Palifermin (keratinocyte growth factor) versus best supportive care measures (BSC) for the decrease of oral mucositis (OM) in lymphoma patients receiving high-dose BEAM-(BCNU, Etoposide, Ara-C, Melphalan) conditioning and autologous stem-cell transplantation (ASCT). Onkologie 34:302.\u00a0https:\/\/doi.org\/10.1159\/000333305","journal-title":"Onkologie"},{"issue":"10","key":"10423_CR21","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/bmt.2011.261","volume":"47","author":"MH Jagasia","year":"2012","unstructured":"Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB et al (2012) Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant 47(10):1350\u20131355.\u00a0https:\/\/doi.org\/10.1038\/bmt.2011.261","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10423_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41409-018-0135-3","volume":"53","author":"V Schmidt","year":"2018","unstructured":"Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C et al (2018) Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 53(9):1188\u20131192.\u00a0https:\/\/doi.org\/10.1038\/s41409-018-0135-3","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10423_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-0609.2009.01336.x","volume":"84","author":"A Chor","year":"2010","unstructured":"Chor A, Torres SR, Maiolino A, Nucci M (2010) Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation. Eur J Haematol 84(2):178\u2013179.\u00a0https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01336.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"10423_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.oraloncology.2010.11.013","volume":"47","author":"S Elad","year":"2011","unstructured":"Elad S, Luboshitz-Shon N, Cohen T, Wainchwaig E, Shapira MY, Resnick IB et al (2011) A randomized controlled trial of visible-light therapy for the prevention of oral mucositis. Oral Oncol 47(2):125\u2013130.\u00a0https:\/\/doi.org\/10.1016\/j.oraloncology.2010.11.013","journal-title":"Oral Oncol"},{"issue":"3","key":"10423_CR25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00520-015-2881-8","volume":"24","author":"B Ferreira","year":"2016","unstructured":"Ferreira B, da Motta Silveira FM, de Orange FA (2016) Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support Care Cancer 24(3):1035\u20131042.\u00a0https:\/\/doi.org\/10.1007\/s00520-015-2881-8","journal-title":"Support Care Cancer"},{"issue":"7","key":"10423_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00520-011-1223-8","volume":"20","author":"BD Hodgson","year":"2012","unstructured":"Hodgson BD, Margolis DM, Salzman DE, Eastwood D, Tarima S, Williams LD et al (2012) Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients. Support Care Cancer 20(7):1405\u20131415.\u00a0https:\/\/doi.org\/10.1007\/s00520-011-1223-8","journal-title":"Support Care Cancer"},{"issue":"8","key":"10423_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10103-017-2263-1","volume":"32","author":"DRN Salvador","year":"2017","unstructured":"Salvador DRN, Soave DF, Sacono NT, de Castro EF, Silva GBL, e Silva LP et al (2017) Effect of photobiomodulation therapy on reducing the chemo-induced oral mucositis severity and on salivary levels of CXCL8\/interleukin 8, nitrite, and myeloperoxidase in patients undergoing hematopoietic stem cell transplantation: a randomized clinical trial. Lasers Med Sci 32(8):1801\u20131810.\u00a0https:\/\/doi.org\/10.1007\/s10103-017-2263-1","journal-title":"Lasers Med Sci"},{"issue":"10","key":"10423_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00520-007-0238-7","volume":"15","author":"MM Schubert","year":"2007","unstructured":"Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA et al (2007) A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15(10):1145\u20131154.\u00a0https:\/\/doi.org\/10.1007\/s00520-007-0238-7","journal-title":"Support Care Cancer"},{"issue":"1","key":"10423_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1089\/pho.2009.2699","volume":"29","author":"GB Silva","year":"2011","unstructured":"Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA (2011) The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg 29(1):27\u201331.\u00a0https:\/\/doi.org\/10.1089\/pho.2009.2699","journal-title":"Photomed Laser Surg"},{"issue":"10","key":"10423_CR30","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1007\/s00520-019-04890-2","volume":"27","author":"Y Zadik","year":"2019","unstructured":"Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun R-J et al (2019) Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27(10):3969\u20133983.\u00a0https:\/\/doi.org\/10.1007\/s00520-019-04890-2","journal-title":"Support Care Cancer"},{"issue":"7","key":"10423_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbmt.2007.03.004","volume":"13","author":"LS Elting","year":"2007","unstructured":"Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C et al (2007) Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 13(7):806\u2013813.\u00a0https:\/\/doi.org\/10.1016\/j.bbmt.2007.03.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10423_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2050","volume":"32","author":"LM Bezinelli","year":"2014","unstructured":"Bezinelli LM, de Paula EF, da Gra\u00e7a Lopes RM, Biazevic MGH, de Paula EC, Correa L et al (2014) Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation. Hematol Oncol 32(1):31\u201339.\u00a0https:\/\/doi.org\/10.1002\/hon.2050","journal-title":"Hematol Oncol"},{"issue":"3","key":"10423_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/TP.0b013e3182558f60","volume":"94","author":"D Seguy","year":"2012","unstructured":"Seguy D, Duhamel A, Rejeb MB, Gomez E, Buhl ND, Bruno B et al (2012) Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation 94(3):287\u2013294.\u00a0https:\/\/doi.org\/10.1097\/TP.0b013e3182558f60","journal-title":"Transplantation"},{"issue":"3","key":"10423_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41430-023-01367-8","volume":"78","author":"S Andersen","year":"2024","unstructured":"Andersen S, Fichera R, Banks M, Brown T, Kennedy G, Weber N et al (2024) Proactive enteral nutrition for patients undergoing allogeneic stem cell transplantation- implementation and clinical outcomes. Eur J Clin Nutr 78(3):251\u2013256.\u00a0https:\/\/doi.org\/10.1038\/s41430-023-01367-8","journal-title":"Eur J Clin Nutr"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10423-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:45:58Z","timestamp":1773215158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10423-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10423"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10423-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}